Vibrating at up to 30,000 times per second, the sonographic device helps tissue to detach more easily without inflicting a large puncture wound to collect an adequate amount of tissue.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
“Dr. Saphier would be a catastrophic mistake on messaging and communicating with MAHA at a time where the coalition is very fragile,” one opponent says.
The Erlangen, Germany-based device manufacturer announced its quarterly earnings results on May 7, which included a 6.5% year-over-year decline in revenue for its diagnostics segment.
First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.
Reports indicate the doctor frequently changed orders and completed alternate exams or procedures without providing clinical documentation to justify the changes.
Although large language models produce appeals letters that are generally deemed useful by readers, they likely still require a babysitter, according to a new analysis.
Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.
A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
